We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 34.27 | 12.31% | 312.6634 | 312.52 | 312.78 | 322.60 | 310.65 | 313.42 | 4,142,681 | 15:34:30 |
From May 2019 to May 2024
By Colin Kellaher
Amgen Inc. (AMGN) and UCB S.A. (UCB.BT) Thursday said the European Commission granted marketing authorization for Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture, marking the first approval of a new osteoporosis medicine in the European Union since 2010.
The companies said they plan the first launches of Evenity, which increases bone formation and reduces bone loss, in the European Economic Area in the first half of 2020.
Amgen, a Thousand Oaks, Calif., biotechnology company, and UCB, a Brussels biopharmaceutical company, are co-developing Evenity under a collaboration and license agreement they inked in 2004.
The European Medicines Agency's Committee for Medicinal Products for Human Use in October recommended approval of the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2019 06:34 ET (11:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
